Traceable Assessment of the Absorbed Power Density of Body Mounted Devices at Frequencies Above 10 GHz

Bioelectromagnetics · 2025 · Unclear · Insufficient evidence

← Research stream
UnclearInsufficient evidencePaper 2559

The study presents a traceable experimental methodology to assess absorbed power density (APD) from body-mounted devices operating above 10 GHz, validated primarily for 24–30 GHz and described as extendable to 10–45 GHz. Validation using reference antennas re…

Study snapshot

PublicationBioelectromagnetics · 2025
Study typeexposure_assessment
Reported directionUnclear
Evidence ratingInsufficient

Abstract

Category: Bioelectromagnetics, Experimental Dosimetry Tags: absorbed power density, body-mounted devices, 5G, skin dosimetry, electromagnetic fields, exposure assessment, wireless safety DOI: 10.1002/bem.70018 URL: onlinelibrary.wiley.com Overview This study introduces a comprehensive and traceable experimental methodology to assess absorbed power density (APD) from body-mounted devices operating at frequencies above 10 GHz—a critical frequency range for modern wireless technologies, including 5G. The method combines: - ✔️ A specialized miniaturized probe - ✔️ A novel composite phantom simulating human skin properties - ✔️ Advanced reconstruction and calibration techniques - ✔️ Rigorous validation processes using reference antennas Findings The proposed solution has been validated primarily for 24 to 30 GHz, but is extendable to 10–45 GHz, ensuring broad utility in current and next-generation wireless device testing. Key achievements include: - 🔹 Development of a composite phantom with enhanced penetration depth, mimicking human skin’s reflection/transmission coefficients for both propagating and evanescent electromagnetic modes. - 🔹 Reliable measurement of induced electromagnetic fields (EMFs) using a broadband probe, with a wide dynamic range and high spatial resolution—essential for regulatory type approval of mobile devices. - 🔹 Probe calibration in a low-uncertainty, traceable setup. - 🔹 System validation using reference antennas, demonstrating expanded uncertainty below 1.6 dB for peak APD and 1.5 dB for peak spatial-averaged APD (psAPD). Summary of Impact - 🌟 First traceable, broadband APD assessment method for 10-45 GHz, validated for practical device testing. - 🌟 Composite phantom design that accurately replicates real-world skin exposure conditions. - 🌟 Reference-antenna-based validation that ensures unbiased, instrumentation-agnostic evaluation across realistic exposure scenarios. Conclusion This work provides a robust foundation for type approval and qualification of body-mounted wireless devices in conformance with international safety standards. By enabling precise APD measurements, the method ensures greater confidence in assessing potential health risks from electromagnetic field (EMF) exposure due to devices operating at millimeter-wave frequencies. Notably, accurate and traceable exposure assessment is vital for understanding, monitoring, and mitigating the health risks connected to EMF exposure from wireless technology.

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typeexposure_assessment
Effect directionunclear
PopulationNot supplied
Sample sizeNot supplied
ExposuremmWave
Evidence strengthInsufficientConfidence: 74% · Peer reviewed: yes

Main findings

The study presents a traceable experimental methodology to assess absorbed power density (APD) from body-mounted devices operating above 10 GHz, validated primarily for 24–30 GHz and described as extendable to 10–45 GHz. Validation using reference antennas reported expanded uncertainty below 1.6 dB for peak APD and 1.5 dB for peak spatial-averaged APD (psAPD).

Outcomes measured

  • Absorbed power density (APD) measurement methodology
  • Peak APD measurement uncertainty
  • Peak spatial-averaged APD (psAPD) measurement uncertainty
  • Skin-equivalent phantom performance (reflection/transmission coefficients; penetration depth)
  • Probe calibration and validation using reference antennas
View raw extracted JSON
{
  "study_type": "exposure_assessment",
  "exposure": {
    "band": "mmWave",
    "source": "body-mounted devices",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": null
  },
  "population": null,
  "sample_size": null,
  "outcomes": [
    "Absorbed power density (APD) measurement methodology",
    "Peak APD measurement uncertainty",
    "Peak spatial-averaged APD (psAPD) measurement uncertainty",
    "Skin-equivalent phantom performance (reflection/transmission coefficients; penetration depth)",
    "Probe calibration and validation using reference antennas"
  ],
  "main_findings": "The study presents a traceable experimental methodology to assess absorbed power density (APD) from body-mounted devices operating above 10 GHz, validated primarily for 24–30 GHz and described as extendable to 10–45 GHz. Validation using reference antennas reported expanded uncertainty below 1.6 dB for peak APD and 1.5 dB for peak spatial-averaged APD (psAPD).",
  "effect_direction": "unclear",
  "limitations": [],
  "evidence_strength": "insufficient",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "absorbed power density",
    "APD",
    "peak APD",
    "psAPD",
    "body-mounted devices",
    "millimeter-wave",
    "mmWave",
    "5G",
    "skin dosimetry",
    "phantom",
    "probe calibration",
    "traceability",
    "exposure assessment",
    "type approval",
    "wireless safety"
  ],
  "suggested_hubs": [
    {
      "slug": "5g-policy",
      "weight": 0.52,
      "reason": "Focuses on mmWave frequencies relevant to 5G and compliance/type-approval exposure assessment above 10 GHz."
    }
  ]
}
AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.1002/bem.70018
PubMed: Not supplied

Read the original paper →

Related papers

← Back to the Research Library